<DOC>
	<DOC>NCT03058029</DOC>
	<brief_summary>This study will asses the effect of Gelesis200 on body weight in overweight and obese subjects with prediabetes and metformin-treated type 2 diabetes.</brief_summary>
	<brief_title>Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects With Prediabetes and Metformin-treated Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<criteria>Body Mass Index (BMI) ≥27 and ≤40 kilogram (kg)/meter (M)2 with body weight &lt;120 kg Prediabetic subjects with FPG ≥100 milligram (mg)/deciliter (dL) and &lt;126 mg/dL [≥5.6 millimole (mmol)/liter (L) and &lt;7.0 mmol/L] at both Screening Visits with HbA1c ≤6.4% [if only 1 value is within this range, the other value should not be ≥126 mg/dL (≥7.0 mmol/L) and HbA1c should be ≥5.7% and ≤6.4%] or metformintreated diabetic subjects with FPG ≥70 mg/dL and ≤270 mg/dL (≥3.9 mmol/L and ≤15.1 mmol/L) at both Screening Visits. Fasting serum insulin &lt;20 microunit (mU)/milliliter (mL) at both Screening Visits in prediabetic subjects. Ability to follow verbal and written instructions Consent obtained via signed ICF Pregnancy [or positive serum or urine pregnancy test(s) in females of childbearing potential] Absence of medically approved contraception in females of childbearing potential [exempli gratia (e.g.), hysterectomy, oral contraceptive medications, intrauterine device combined with a barrier method, two (2) combined barrier methods such as diaphragm and condom or spermicide, or condom and spermicide; bilateral tubal ligation and vasectomy are acceptable contraceptive methods when combined with another single method from above] History of allergic reaction to carboxymethylcellulose (CMC), citric acid, maltodextrin, gelatin, or titanium dioxide Participation in a weight loss study within the past twelve (12) months Administration of Gelesis100 or Gelesis200 in a previous study Administration of investigational products within one (1) month prior to Screening Visit Smoking cessation within six (6) months prior to Screening Visit or considering smoking cessation during the study Anticipated surgical intervention during the study period Known Type 1 Diabetes History of eating disorders including binge eating (except for mild binge eating) or emesis ≥2/week from any cause Weight change &gt;3% within three (3) months prior to and during the Screening period Supine systolic blood pressure (SBP) &gt;160 millimeters of mercury (mmHg) and/or supine diastolic blood pressure (DBP) &gt;95 mmHg Angina, coronary bypass, or myocardial infarction within six (6) months prior to Screening Visit History of swallowing disorders Esophageal anatomic abnormalities (e.g., webs, diverticuli, rings) History of gastroesophageal reflux disease History of gastric or duodenal ulcer History of gastroparesis (e.g., chronic nausea, vomiting ≥2 occurrences per week, heartburn, etc.) History of gastric bypass or any other gastric surgery History of small bowel resection (except if related to appendectomy) History of intestinal stricture (e.g., Crohn's disease) History of intestinal obstruction or high risk of intestinal obstruction, including suspected small bowel adhesions History of abdominal radiation treatment History of pancreatitis within the past 12 months History of malabsorption Laxative users, except those on stable doses within one (1) month prior to Screening Visit History of hepatitis B or C History of human immunodeficiency virus (HIV) History of cancer within the past five (5) years (except adequatelytreated localized basal cell skin cancer or in situ uterine cervical cancer) Any other clinically significant disease interfering with the assessments of Gelesis200 (e.g., disease requiring corrective treatment, potentially leading to study discontinuation) Abnormal serum thyroidstimulating hormone (TSH) HbA1c &gt;8.5% (&gt;69 mmol/mole (mol)) Serum lowdensity lipoprotein (LDL) cholesterol ≥160 mg/dL (≥4.15 mmol/L) Serum triglycerides ≥350 mg/dL (≥3.96 mmol/L) Positive test for drugs of abuse in the urine Any relevant biochemical abnormality interfering with the assessments of Gelesis200 Antiobesity medications (including herbal preparations) within one (1) month prior to Screening Visit Systemic corticosteroids within one (1) month prior to Screening Visit Thyroid hormones or preparations within one (1) month prior to Screening Visit [except stable dose of replacement therapy for at least two (2) months] TSH suppression therapy for thyroid cancer Estrogen within one (1) month prior to Screening Visit [except stable dose of replacement therapy or contraceptives for at least one (1) month] Any other medication known to cause weight loss or weight gain within one (1) month prior to Screening Visit Antidiabetic medications within one (1) month prior to Screening Visit [except stable doses of metformin for at least one (1) month in subjects with Type 2 Diabetes] Change in medications treating hypertension within one (1) month prior to Screening Visit Change in medications treating dyslipidemia within one (1) month prior to Screening Visit Anticipated requirement for use of prohibited concomitant medications Any other condition that, in the opinion of the Investigator or Sponsor, would interfere with the subject's ability to participate in the study</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>